Kinarus Therapeutics (SIX: KNRS)

Last close As at 26/02/2024

0.00

0.00 (0.00%)

Market capitalisation

1m

Edison Investment Research is terminating coverage on Kinarus Therapeutics (KNRS). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Latest Insights

View More

Healthcare | Flash note

Kinarus Therapeutics — Kinarus secures CHF1.5m financing

Healthcare | Flash note

Kinarus Therapeutics — USPTO allows method-of-use KIN001 patent

Healthcare | Flash note

Kinarus Therapeutics — KINETIC study discontinued

Sector

Healthcare

Balance Sheet

Forecast net debt (CHFm)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (80.0) (84.8) (89.2)
Relative (79.6) (84.3) (89.8)
52 week high/low CHF0.0/CHF0.0

Financials

Edison Investment Research is terminating coverage on Kinarus Therapeutics (KNRS), Numis Corporation (NUM), EMIS Group (EMIS), Pixium Vision (PIX) and Treatt (TET). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Previously published reports can still be accessed via website

Y/E Dec Revenue (CHFm) EBITDA (CHFm) PBT (CHFm) EPS (fd) (CHFc) P/E (x) P/CF (x)
2020A 0.0 (1.5) (1.5) (31.17) N/A N/A
2021A 0.0 (5.1) (4.9) (0.41) N/A N/A
2022E N/A N/A N/A N/A N/A N/A
2023E N/A N/A N/A N/A N/A N/A

Thematics

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

thematic

Healthcare

ASCO 2023 key takeaways

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free